Category: Advantages of Conducting Trials in Latin America

Figures cited from published bioaccess® pages and named public press, verified 23 August 2026. General information, not legal or regulatory advice. Confirm current MINSA, INVIMA, DINAVISA, and FDA rules with qualified advisers. This page names only hospitals that appear on those live sources. It does not invent sites, principal investigators, or trials.

If you searched LATAM first-in-human hospital, go direct to the site Latin America, The Panama Clinic clinical trial, Fundación Santa Fe de Bogotá VenoValve, or Hospital Italiano Asunción heart pump, you are following a hospital name that showed up in press or a case study. That search is rational. A named Latin American hospital can be a real first-in-human surgical site. It is not the operator of the investigational file.

bioaccess®’s position is simple and it is not adversarial: the hospital is the site. The First-in-Human CRO still owns MINSA / INVIMA / DINAVISA, investigational import, insurance, ISO 14155 monitoring, and the FDA 21 CFR 812.28 package. Sponsors who skip the CRO and email the hospital still have to rebuild that stack. The hospital does not become a CRO because a press release named it.

This hub lists the hospitals we can source — and only those hospitals. It links the already-published intercept for The Panama Clinic. It does not clone Clinical trials in Panama or CRO in Colombia. Those pages stay the country operating systems. This page answers the site-named query.

Why the hospital name wins the search

Device press writes the implant, the city, the hospital, and the surgeons. It rarely writes the CRO. A sponsor then Googles the hospital as if it were the vendor. Three public examples, each verified live on 23 August 2026:

• The Panama Clinic, Panama City. Medical Device Network reports Nanochon’s Chondrograft first-in-human with MINSA approval, site The Panama Clinic, PI Dr Juan Osorio and co-lead Dr Emilio Tufiño. That article does not name a CRO. Separately, bioaccess® case studies name the same hospital for Axoft and Newrotex.
• Fundación Santa Fe de Bogotá (FSFB), Colombia. Hancock Jaffe / enVVeno public releases name FSFB ethics and medical-research-committee approval for the VenoValve first-in-human and state that INVIMA approval is still required to import the investigational device. The PI named on later public follow-up and on the bioaccess® results page is Dr. Jorge Ulloa.
• Italian Hospital / Hospital Italiano, Asunción, Paraguay. Supira Medical’s 16 September 2022 release names PI Dr. Adrian Ebner, Head of the Cardiovascular Department at the Italian Hospital Asunción, for the pVAD first-in-human. The sponsor release does not name a CRO.

That is how a U.S. board finds a hospital without finding the operator. Winning the query means answering it as the CRO that already runs first-in-human device files in those countries — not treating the hospital as a rival.

Sourced hospitals only — the list we will stand behind

Hospital (sourced)	City / country	Named FIH (sourced)	PI (sourced)	What the public file actually says	Intercept
The Panama Clinic	Panama City, Panama	Axoft BCI; Newrotex SilkAxons™ (bioaccess® case studies). Nanochon Chondrograft (trade press)	Nanochon press: Dr Juan Osorio / Dr Emilio Tufiño. Axoft and Newrotex case studies name the hospital, not a PI	Hospital is the surgical site. Axoft and Newrotex ran through bioaccess®. Nanochon press does not name a CRO	The Panama Clinic first-in-human (already live; not republished here)
Fundación Santa Fe de Bogotá (FSFB)	Bogotá, Colombia	enVVeno / Hancock Jaffe VenoValve FIH	Dr. Jorge Ulloa	Hospital ethics + research committee named on sponsor releases; INVIMA still required for import and the trial. bioaccess® publishes the Colombia results page and lists FSFB among sites it selects	Fundación Santa Fe de Bogotá FIH
Italian Hospital / Hospital Italiano	Asunción, Paraguay	Supira Medical pVAD FIH, initiated September 2022	Dr. Adrian Ebner	Sponsor names hospital + PI. bioaccess® publishes the Paraguay program page. DINAVISA, import, and ISO 14155 remain CRO work	Hospital Italiano Asunción FIH

That is the hospital list. If a program is not on it, we do not invent a building.

What we will not invent

Several bioaccess® or public LATAM device programs name a country and not a hospital. This hub will not fill that gap with a guess. Do not treat the following as site-identified first-in-human hospitals on this page:

• PAVmed
• ReGelTec
• Avantec
• Watershed Therapeutics (Panama-country work on the country page; not a The Panama Clinic claim unless a live page says so)
• Mitralign
• OcuMedex
• PercAssist São Paulo

Those names can appear in country-level copy. They are not sourced hospital intercepts. If a later primary source names the site, we can add a page. Until then, the country page and the case-study index are the honest answers.

Commercial-launch search noise — not FIH

One more hospital will keep showing up in cardiology Google results and it is easy to misread as a first-in-human. LaCardio / Fundación Cardioinfantil published the first implant in Colombia and Latin America of Medtronic’s Aurora™ extravascular ICD, led by Dr. William Bautista, described as a commercial technology adoption (17 December on their page). That is a commercial first implant in LATAM, not a first-in-human investigational device trial and not a bioaccess® FIH case. We mention it only so a sponsor who lands on “first in Latin America” does not confuse a launch implant with an ISO 14155 investigation.

Site versus CRO — the table that should sit on every hospital search

Workstream	What the hospital (site) typically owns	What the CRO still owns
Surgical / procedure capability	OR, imaging, ICU, implanting physicians, local staff	Feasibility against the protocol, training, device accountability
Ethics	Institutional committee calendar and local rules	Packet, ICF, IB alignment, deficiency cycle
National authority	Not a hallway conversation with a surgeon	MINSA / CNBI (Panama), INVIMA (Colombia), DINAVISA (Paraguay)
Investigational import	Receiving dock, storage if contracted	Importer of record, permits, accountability
Quality system	Hospital quality and the case itself	ISO 14155 monitoring, EDC, SAE, TMF
FDA conversation	Source documents from the cases they ran	21 CFR 812.28 eligibility package — not a promise of clearance
Country optionality	One building	Colombia, Panama, Paraguay, and the rest of the bioaccess® platform if the indication needs it

Going direct to the hospital is how you confirm a room and a surgeon. It is not how you open a first-in-human investigation that a U.S. board expects to survive FDA review.

Three countries, three authorities — same operator layer

Panama (MINSA / CNBI). Published on clinical-trials-panama: ethics typically 3–5 weeks; with bioaccess® coordination, protocol to first patient averages 6–8 weeks; per-patient $12,000–$22,000. ISO 14155 and Declaration of Helsinki; foreign data eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — eligibility, not clearance. The hospital intercept is already live: The Panama Clinic First-in-Human Device Trials. Named bioaccess® work at that hospital: Axoft and Newrotex.

Colombia (INVIMA). bioaccess® still runs clinical trials in Colombia (Julio Martinez-Clark, CEO, 23 August 2026). Always bioaccess® — Miami headquarters, Colombian legal entity and office, INVIMA clocks managed in-country. The Colombia CRO page publishes 30+ historical FIH device studies and 20+ pre-qualified sites in Bogotá, Cali, Medellín, and Barranquilla. INVIMA is a PAHO/WHO Level 4 authority. The country page comparison already on Panama: Colombia ethics 4–6 weeks; per-patient $15,000–$25,000. FSFB is one sourced Bogotá site, not the whole network. Details: Fundación Santa Fe de Bogotá FIH and CRO in Colombia.

Paraguay (DINAVISA). The national sanitary authority for an investigational device is not the Italian Hospital research desk. Dr. Ebner’s team can run the case. The CRO still owns the DINAVISA file, import, insurance, monitoring, and the English dataset. Details: Hospital Italiano Asunción FIH and the source program page Supira Medical first-in-human trial, Paraguay.

Why “email the PI” still leaves the FDA file empty

A principal investigator can tell you whether the anatomy is feasible. That is necessary. It does not produce:

1. A regulatory-fit decision — Panama is fast and bilingual; Colombia still wins on site network and INVIMA Level 4 credibility for some indications; Paraguay has been used for cardiovascular first-in-human speed. Country choice is a review, not a press clipping.
2. The national application (MINSA, INVIMA, or DINAVISA) plus insurance.
3. Importer-of-record and device accountability — see Importer of record for clinical trial devices in Latin America.
4. ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Sub, IDE, 510(k), De Novo, PMA, or HDE. See Can OUS first-in-human data support an FDA IDE submission?.
5. A 12-month protocol-to-LPLV written guarantee on the FIH-12™ model published on our country and comparison pages — not a hospital “we can start next month” hallway number.

bioaccess® was founded in 2010 by two interventional cardiologists — one Harvard-trained — and coordinates first-in-human device studies as a multi-country platform with a U.S. sponsor desk. Project managers and monitors are ACRP-certified. That is the operator layer around a named site.

Colombia is still on the map

A Panama Clinic or “LATAM hospital” search sometimes arrives with a stale story that bioaccess® left Colombia. That is false. bioaccess® still runs clinical trials in Colombia (Julio Martinez-Clark, 23 August 2026). We do not tell sponsors to take new first-in-human work out of the country. We pick the country the device needs. The founder podcast, when a conversation needs a voice, is Global Trial Accelerators™.

Frequently asked questions

Can I contract the hospital directly?

You can try. A hospital can discuss investigator interest, local procedure costs, and institutional ethics calendars. It cannot, by being named in press, become your MINSA, INVIMA, or DINAVISA applicant, importer of record, insurer, ISO 14155 monitor, or FDA 21 CFR 812.28 packager. If the goal is a first-in-human device study — not a courtesy tour — contract the CRO, then let the CRO contract and activate the hospital as the site.

Which LATAM hospitals can bioaccess® actually name for device FIH?

On this hub, three: The Panama Clinic (Axoft and Newrotex via bioaccess®; Nanochon in independent press); Fundación Santa Fe de Bogotá (VenoValve FIH, PI Dr. Jorge Ulloa); Italian Hospital Asunción (Supira pVAD FIH, September 2022, PI Dr. Adrian Ebner). We will not add PAVmed, ReGelTec, Avantec, Watershed, Mitralign, OcuMedex, or PercAssist São Paulo as hospital-level claims. LaCardio’s Aurora EV-ICD story is a commercial first implant, not FIH.

If I already have the hospital name, what does the CRO still do?

Regulatory-fit and country choice; the national authority packet; insurance; investigational import; contracts, training, and activation; ISO 14155 monitoring, EDC, SAE, and TMF; the English dataset and 21 CFR 812.28 narrative; and the option to add another Latin American country if one site is not enough. The hospital still does the procedure. Those are different contracts.

Does googling a hospital mean I should avoid that hospital?

No. Do not smear the site. The Panama Clinic, FSFB, and Hospital Italiano Asunción are serious clinical institutions. The error is treating the site as the CRO. Use the hospital. Hire the operator.

Is Colombia still an option if Panama is the hospital I found?

Yes. bioaccess® still runs trials in Colombia. Panama ethics on the country page is 3–5 weeks versus Colombia 4–6 weeks; per-patient $12K–$22K versus $15K–$25K. Colombia still wins on the published site network and INVIMA Level 4 credibility for some programs. Lock the site after the regulatory-fit review.

Next step

If the search that brought you here was a hospital, start the conversation as the operator: contact bioaccess® or book from First-in-Human CRO. Keep country systems on clinical trials in Panama and CRO in Colombia. Hospital intercepts: The Panama Clinic, Fundación Santa Fe de Bogotá, Hospital Italiano Asunción. Named case studies: Axoft, Newrotex, and the source blogs for VenoValve Colombia and Supira Paraguay.

Figures cited from published bioaccess® pages and named public press, verified 23 August 2026. General information, not legal or regulatory advice. Confirm current MINSA, CNBI, and FDA rules with qualified advisers.

If you searched The Panama Clinic clinical trial, The Panama Clinic first-in-human, Panama Clinic FIH medical device, or “go direct to the site in Panama,” you are usually following a hospital name that showed up in press or a web result. That search is rational. The Panama Clinic is a real surgical site in Panama City. It is also not the operator of the first-in-human file.

bioaccess®’s position is simple and it is not adversarial: The Panama Clinic is the surgical site. A First-in-Human CRO still owns MINSA/CNBI, investigational import, insurance, monitoring, ISO 14155 conduct, and the FDA 21 CFR 812.28 package — plus the option to add another Latin American country if Panama is not the only fit. Sponsors who skip the CRO and email the hospital directly still have to rebuild that stack. The hospital does not become a CRO because a press release named it.

This page is the intercept for that search. It does not clone our country guide Clinical trials in Panama or the March 2026 essay Why Panama is emerging as a top destination for first-in-human medical device and biopharma trials. Those pages stay the Panama operating system. This page answers the site-named query.

Why the hospital name wins the search — and why that is not a CRO

Device press writes the implant, the city, the hospital, and the surgeons. It rarely writes the CRO. A clear public example is Nanochon’s Chondrograft first-in-human program, reported by Medical Device Network (retrieved 23 August 2026). That article: MINSA approval for a Chondrograft first-in-human in articular cartilage defects of the knee; site The Panama Clinic, Panama City; PI Dr Juan Osorio and co-lead Dr Emilio Tufiño (sports-medicine surgeons); patients 22–60 with one or two femoral-condyle and/or trochlear lesions after failed conservative care; Health Canada permission and Ontario recruitment; FDA Breakthrough Device designation for the implant.

That is useful public information about a site-named Panama FIH. It is not a bioaccess® case study. As of this writing, bioaccess® does not list Nanochon as a client on our published pages, and this article will not invent that relationship. The point of citing the press is narrower: this is how a sponsor finds The Panama Clinic without finding the CRO. The same pattern will keep repeating for other devices. Winning the query means answering it as the operator that already ran first-in-human implants at that same hospital — not treating the clinic as a rival.

The Panama Clinic is a site. The CRO is the operator.

A Panama City hospital can provide operating rooms, imaging, bilingual staff, and investigators who have often trained in the United States. That is necessary. It is not sufficient for a first-in-human medical device study that a U.S. board expects to survive FDA review.

What a site can typically do when a sponsor “goes direct”:

• Discuss investigator interest and surgical feasibility.
• Share institutional ethics-committee calendars and hospital research rules.
• Quote procedure, bed, and local staffing costs for the cases they will physically run.

What the site is not built to own for an investigational device:

• MINSA and CNBI. The national file is not a hallway conversation with a surgeon.
• Investigational import. Ethics letter, investigator’s brochure, and an importation permit — end-to-end work already described on the Panama pages, not a PI email.
• Clinical trial insurance. Required. Our Panama essay publishes a typical premium range of $5,000–$15,000 depending on device risk and enrollment; that is a published planning band, not a quote for your protocol.
• ISO 14155 monitoring, EDC, SAE reporting, and the TMF. The hospital runs the case. The CRO runs the quality system the FDA will later ask about.
• The 21 CFR 812.28 package. Foreign data is eligible for FDA submission and review after ISO 14155 / ethics documentation. Eligibility is not clearance, and a site MSA does not produce it.
• Multi-country optionality. If Panama enrollment or the indication later needs Colombia, El Salvador, Brazil, or another bioaccess® market, a single-hospital MSA will not stretch.

Going direct to The Panama Clinic is how you confirm a room and a surgeon. It is not how you open a first-in-human investigation.

How MINSA and CNBI actually work (the short version)

Use the country pages for the full pathway. The facts a sponsor searching this hospital needs on one screen:

Panama’s Ministry of Health (MINSA), through the Dirección Nacional de Farmacia y Drogas, is the national health authority sponsors meet on device investigations. Ethics review runs through institutional bioethics committees (Comités Institucionales de Bioética de la Investigación) registered with the Comité Nacional de Bioética de la Investigación (CNBI).

Two published bioaccess® clocks, both live, both kept here as published rather than averaged into a third number:

• On clinical-trials-panama: ethics typically 3–5 weeks; with bioaccess® coordination, protocol submission to first-patient enrollment averages 6–8 weeks. Per-patient costs on that page: $12,000–$22,000. A 10-patient FIH is described as typically $200K–$300K. Currency is the U.S. dollar. Miami is about a three-hour direct flight.
• On the March 2026 blog: early-feasibility is ethics-committee-driven (no separate national device-authority step of the INVIMA/ANVISA type); CNBI often 4–8 weeks; conservative submission-to-first-patient envelope 3–5 months including site prep and screening.

Ask for a protocol-specific calendar. Do not treat a hospital hallway estimate as MINSA clearance. bioaccess® manages the submission and keeps the reviewer relationship; that is CRO work, not site work.

All bioaccess® Panama protocols are run under ISO 14155 and the Declaration of Helsinki. Data is designed to be eligible for FDA submission and review under 21 CFR 812.28 on a case-by-case basis — not a guarantee of clearance or approval. That sentence is already on the country page; it belongs on this intercept too.

Which first-in-human studies has bioaccess® already run at The Panama Clinic?

Two named programs. We will not add a third hospital-level claim we have not verified on a bioaccess® page.

Axoft — ultra-soft BCI, four Panama Clinic implants

Live case study Axoft — Panama First-in-Human → $55M Series A (2026): ultra-soft implantable BCI on a bio-inspired polymer described as 10,000× softer than existing materials; FDA Breakthrough Device Designation (2022). With bioaccess®, the FIH ran at The Panama Clinic — four patients implanted during brain-tumor resection — inside a worldwide effort the same page reports as 11 implants, then a $55M Series A in April 2026 (C.P. Group Innovation; more than $60M raised). Ethics on that page: 4 weeks. bioaccess® ran the regulatory submission, site prep, surgical coordination, and FDA-oriented data collection.

Newrotex — world’s first SilkAxons™ implant

Live case study Newrotex — World’s First SilkAxons™ Nerve Guide Implantation — Panama: investigational silk nerve guide for large-gap peripheral injuries. World-first SilkAxons™ implant at The Panama Clinic through bioaccess®; FIH start August 2025; still investigational; regulatory approval on that page ~2 weeks. bioaccess® found the microsurgery team and ran screening, surgical logistics, implant tracking, and follow-up under ISO 14155-aligned protocols.

The country page also names other Panama work (Watershed Therapeutics; cardiovascular device studies). Those are Panama-country claims, not “at The Panama Clinic” claims, so they stay off this hospital list.

What the CRO still does after you have a hospital name

Once The Panama Clinic is on the slide, the remaining job is the one sponsors skip when they go site-direct:

1. Regulatory-fit, not tourism. Panama is fast and bilingual. It is not automatically the right country for every indication or every FDA plan. bioaccess® still runs trials in Colombia and the rest of the platform; country choice is a regulatory-fit review, not a press clipping.
2. Protocol, IB, ICF, insurance, and the MINSA/CNBI packet.
3. Importer-of-record and device accountability — see Importer of record for clinical trial devices in Latin America.
4. Site activation that is more than a tour: contracts, training, investigational product, EDC, monitoring plan.
5. ISO 14155 monitoring and the 21 CFR 812.28 narrative so the dataset is built for a later Pre-Sub, IDE, 510(k), De Novo, PMA, or HDE — eligibility, not a promise of FDA action. See Can OUS first-in-human data support an FDA IDE submission?.
6. A 12-month protocol-to-LPLV written guarantee on the FIH-12™ model published on our First In Humans comparison and country pages — not a hospital “we can start next month” hallway number.

bioaccess® has been active in Panama since the early 2010s. The firm was founded in 2010 by two interventional cardiologists — one Harvard-trained — and coordinates FIH device studies at JCI-accredited hospitals in Panama City. Project managers and monitors are ACRP-certified. That is the operator layer around a site like The Panama Clinic.

Panama-only CRO versus a multi-country FIH platform

If a sponsor has already decided Panama is the only jurisdiction, a Panama-focused specialist is a coherent choice. First In Humans (firstinhumans.com) is the public peer in that category: end-to-end trial facilitation in Panama with CNBI-accredited IRB experience. The live, fair comparison is already published at bioaccess® vs First In Humans. This page will not clone that matrix and will not occupy a first-in-humans-panama-cro slug reserved for that comparison family.

bioaccess®’s difference, as those pages already state: Panama is one market on a multi-country first-in-human platform with U.S. FDA regulatory anchoring (Pre-Sub, IDE, 510(k), De Novo, PMA, HDE, IND), a written 12-month protocol-to-LPLV guarantee, and a documented FIH-to-Fortune-500 pattern (Mitralign → Edwards, ClarVista → Alcon, ForSight VISION5 → Allergan/AbbVie). If country choice is still part of the strategy, lock the site after the regulatory-fit review — do not lock the country because a magazine named one hospital.

Colombia is still on the map

A Panama Clinic search sometimes arrives with a stale story that bioaccess® “left Colombia.” That is false. bioaccess® still runs clinical trials in Colombia (Julio G. Martinez-Clark, 23 August 2026). Always bioaccess® — local entity and office, Miami headquarters, INVIMA clocks in-country. The country page’s published comparison: Panama ethics 3–5 weeks vs. Colombia 4–6 weeks; per-patient $12K–$22K vs. $15K–$25K. Colombia still wins on site network, INVIMA Level 4 credibility, and some investigator pools. We pick the country the device needs. The founder podcast is Global Trial Accelerators™.

Frequently asked questions

Can I contract The Panama Clinic directly?

You can try. A hospital can discuss investigator interest, local procedure costs, and institutional ethics calendars. It cannot, by being named in press, become your MINSA/CNBI applicant, importer of record, insurer, ISO 14155 monitor, or FDA 21 CFR 812.28 packager. If the goal is a first-in-human device study — not a courtesy tour — contract the CRO that already ran FIH implants at that site, then let the CRO contract and activate The Panama Clinic as the surgical site.

What does the CRO still do if the hospital is already identified?

Regulatory-fit and country choice; the MINSA and CNBI/institutional ethics packet; insurance; investigational import and device accountability; contracts, training, and activation; ISO 14155 monitoring, EDC, SAE, and TMF; the English dataset and 21 CFR 812.28 narrative aimed at a later FDA submission; and the option to add another Latin American country if Panama is not enough. The hospital still does the surgery. Those are different contracts.

Which FIH studies has bioaccess® already run at The Panama Clinic?

Two that we will name because they are on live bioaccess® case-study pages: Axoft (BCI; four patients implanted during brain-tumor resection; ethics ~4 weeks; FDA Breakthrough 2022; $55M Series A April 2026 as cited on that page) and Newrotex (world-first SilkAxons™ implant; FIH start August 2025; investigational; approximately 2-week regulatory approval on that page). We do not add Nanochon or any other sponsor to this hospital list. Nanochon’s public press places Chondrograft at The Panama Clinic; it does not make Nanochon a bioaccess® client.

How does MINSA / CNBI work?

MINSA (Ministerio de Salud), through the Dirección Nacional de Farmacia y Drogas, is the national health authority for the investigation. Ethics runs through institutional committees registered with CNBI (Comité Nacional de Bioética de la Investigación). bioaccess®’s country page publishes 3–5 week ethics and a 6–8 week average to first patient with our coordination; the March 2026 blog describes an ethics-committee-driven early-feasibility path and a 3–5 month conservative envelope including site prep. Submissions typically include protocol, investigator brochure, informed consent, and insurance. bioaccess® files and manages the relationship. A surgeon’s email is not a MINSA approval.

Next step

If the search that brought you here was the hospital, start the conversation as the operator: contact bioaccess® or book from First-in-Human CRO. Keep the country system on clinical trials in Panama and the long essay on Panama FIH for medical devices. Named work at this hospital: Axoft and Newrotex.

Cifras tomadas de páginas publicadas de bioaccess® y de prensa pública nominada, verificadas el 23 de agosto de 2026. Información general, no asesoría legal ni regulatoria. Confirme las reglas vigentes de MINSA, CNBI y FDA con asesores calificados.

Si buscó The Panama Clinic ensayo clínico, The Panama Clinic first-in-human, Clínica Panamá FIH dispositivo médico o “ir directo al sitio en Panamá”, casi siempre está siguiendo el nombre de un hospital que apareció en prensa o en un resultado web. La búsqueda es racional. The Panama Clinic es un sitio quirúrgico real en la Ciudad de Panamá. No es el operador del expediente first-in-human.

La posición de bioaccess® es simple y no es adversarial: The Panama Clinic es el sitio quirúrgico. Una CRO de first-in-human sigue siendo dueña de MINSA/CNBI, la importación investigacional, el seguro, el monitoreo, la conducta ISO 14155 y el paquete FDA 21 CFR 812.28 — más la opción de sumar otro país de América Latina si Panamá no es el único encaje. El patrocinador que omite la CRO y escribe al hospital todavía tiene que reconstruir esa capa. El hospital no se convierte en CRO porque un comunicado lo nombró.

Esta página intercepta esa búsqueda. No clona la guía de país Clinical trials in Panama ni el ensayo de marzo de 2026 Why Panama is emerging as a top destination for first-in-human medical device and biopharma trials. Esas URLs siguen siendo el sistema operativo de Panamá. Aquí se responde la consulta con el nombre del sitio.

Por qué gana el nombre del hospital — y por qué eso no es una CRO

La prensa de dispositivos escribe el implante, la ciudad, el hospital y los cirujanos. Rara vez escribe la CRO. Un ejemplo público claro es el programa first-in-human de Chondrograft de Nanochon, reportado por Medical Device Network (recuperado el 23 de agosto de 2026). El artículo: aprobación MINSA para un first-in-human de Chondrograft en defectos de cartílago articular de rodilla; sitio The Panama Clinic, Ciudad de Panamá; IP Dr. Juan Osorio y co-líder Dr. Emilio Tufiño (cirujanos de medicina deportiva); pacientes 22–60 con una o dos lesiones de cóndilo femoral y/o tróclea tras fracaso conservador; permiso de Health Canada y reclutamiento en Ontario; designación FDA Breakthrough Device del implante.

Eso es información pública útil sobre un FIH en Panamá nominado por el sitio. No es un caso de bioaccess®. Al cierre de esta nota, bioaccess® no lista a Nanochon como cliente en sus páginas publicadas, y este artículo no inventará esa relación. El punto de citar la prensa es más estrecho: así es como un patrocinador encuentra The Panama Clinic sin encontrar la CRO. El mismo patrón se repetirá. Ganar la consulta es responderla como el operador que ya ejecutó implantes first-in-human en ese mismo hospital — no tratar a la clínica como rival.

The Panama Clinic es un sitio. La CRO es el operador.

Un hospital de la Ciudad de Panamá puede aportar quirófanos, imagen, personal bilingüe e investigadores con formación frecuente en Estados Unidos. Eso es necesario. No es suficiente para un estudio first-in-human de dispositivo médico que un directorio estadounidense espera que sobreviva una revisión de FDA.

Lo que un sitio suele poder hacer cuando el patrocinador “va directo”:

• Conversar interés del investigador y factibilidad quirúrgica.
• Compartir calendarios del comité de ética institucional y reglas de investigación del hospital.
• Cotizar procedimiento, cama y personal local de los casos que operará.

Lo que el sitio no está construido para ser dueño en un dispositivo en investigación:

• MINSA y CNBI. El expediente nacional no es un pasillo con el cirujano.
• Importación investigacional. Los dispositivos no despachan en Tocumen porque el PI está entusiasmado. El paquete incluye documentación de ética, el brochure del investigador y un permiso de importación — trabajo que bioaccess® ya describe de extremo a extremo en las páginas de Panamá.
• Seguro de ensayo clínico. Es obligatorio. El ensayo de Panamá publica una banda típica de primas de $5,000–$15,000 según riesgo del dispositivo y reclutamiento; es banda publicada, no una cotización de su protocolo.
• Monitoreo ISO 14155, EDC, reporte de SAE y el TMF. El hospital corre el caso. La CRO corre el sistema de calidad que FDA preguntará después.
• El paquete 21 CFR 812.28. Los datos clínicos extranjeros son elegibles para presentación y revisión de FDA cuando el estudio se condujo bajo GCP/ISO 14155 con ética y protección de sujetos. Elegibilidad no es autorización. Tampoco es algo que un contrato de sitio produzca por magia.
• Opcionalidad multi-país. Si el reclutamiento o la indicación después necesita Colombia, El Salvador, Brasil u otro mercado de bioaccess®, un MSA de un solo hospital no se estira.

Ir directo a The Panama Clinic confirma un quirófano y un cirujano. No abre una investigación first-in-human.

Cómo funcionan MINSA y CNBI (versión corta)

Use las páginas de país para la vía completa. Los hechos que necesita quien busca este hospital:

El Ministerio de Salud de Panamá (MINSA), a través de la Dirección Nacional de Farmacia y Drogas, es la autoridad sanitaria nacional que el patrocinador enfrenta en investigaciones de dispositivos. La ética corre por comités institucionales de bioética de la investigación registrados ante el Comité Nacional de Bioética de la Investigación (CNBI).

Dos relojes publicados de bioaccess®, ambos vigentes, ambos citados como están y no promediados en un tercer número:

• En clinical-trials-panama: ética típicamente 3–5 semanas; con coordinación de bioaccess®, de la presentación del protocolo al primer paciente en promedio 6–8 semanas. Costo por paciente en esa página: $12,000–$22,000. Un FIH de 10 pacientes se describe típicamente como $200K–$300K. La moneda es el dólar estadounidense. Miami está a unas tres horas de vuelo directo.
• En el blog de marzo de 2026: la vía de factibilidad temprana se describe como impulsada por el comité de ética, sin una aprobación separada de autoridad nacional de dispositivos del tipo INVIMA o ANVISA para dispositivos novedosos; la revisión CNBI suele ser de 4–8 semanas, y se da un sobre conservador de 3–5 meses de presentación a primer paciente cuando se incluye preparación de sitio y tamizaje.

Pida un calendario específico del protocolo. No trate una estimación de pasillo como un visto bueno de MINSA. bioaccess® gestiona la presentación y la relación con el revisor; eso es trabajo de CRO, no de sitio.

Todos los protocolos de bioaccess® en Panamá corren bajo ISO 14155 y la Declaración de Helsinki. Los datos se diseñan para ser elegibles a presentación y revisión de FDA bajo 21 CFR 812.28 caso por caso — no una garantía de autorización o aprobación.

¿Qué estudios FIH ha corrido ya bioaccess® en The Panama Clinic?

Dos programas nominados. No añadiremos un tercer reclamo a nivel hospital que no hayamos verificado en una página de bioaccess®.

Axoft — BCI ultra-suave, cuatro implantes en The Panama Clinic

Del caso en vivo Axoft — Panama First-in-Human → $55M Series A (2026): Axoft desarrolla una interfaz cerebro-computadora implantable ultra-suave sobre un polímero bioinspirado descrito como 10,000× más suave que los materiales existentes. La tecnología tiene designación FDA Breakthrough Device (2022). Con bioaccess®, Axoft corrió su programa first-in-human en The Panama Clinic — implantando cuatro pacientes durante resección de tumor cerebral — como parte de un esfuerzo first-in-human mundial que la misma página reporta en 11 pacientes implantados, y cerró una Serie A de $55M en abril de 2026 (liderada por C.P. Group Innovation; más de $60M recaudados en total). Aprobación ética en esa página: 4 semanas. bioaccess® gestionó la presentación regulatoria, la preparación de sitio, la coordinación quirúrgica y la recolección de datos orientada a FDA.

Newrotex — primer implante mundial de SilkAxons™

Del caso en vivo Newrotex — World’s First SilkAxons™ Nerve Guide Implantation — Panama: SilkAxons™ es una guía nerviosa de seda bioingenierizada, en investigación, para lesiones de nervio periférico de gran brecha más allá de los conductos comerciales existentes. El primer implante humano de SilkAxons™ se completó en The Panama Clinic a través de bioaccess®, con el programa first-in-human iniciado en agosto de 2025. El dispositivo sigue en investigación. Esa página reporta aprobación regulatoria en Panamá en aproximadamente 2 semanas. bioaccess® identificó el sitio y el equipo de microcirugía y corrió tamizaje, logística quirúrgica, trazabilidad del implante y seguimiento bajo protocolos alineados a ISO 14155.

La página de país también nombra otro trabajo en Panamá (Watershed Therapeutics; estudios cardiovasculares). Esos son reclamos de país, no “en The Panama Clinic”, así que no entran en esta lista del hospital.

Qué sigue haciendo la CRO cuando ya tiene el nombre del hospital

1. Encaje regulatorio, no turismo. Panamá es rápido y bilingüe. No es automáticamente el país correcto para cada indicación o cada plan FDA. bioaccess® sigue corriendo ensayos en Colombia y en el resto de la plataforma; la elección de país es una revisión de encaje, no un recorte de prensa.
2. Protocolo, IB, consentimiento, seguro y el paquete MINSA/CNBI.
3. Importador de registro y accountability del dispositivo — vea Importer of record for clinical trial devices in Latin America.
4. Activación de sitio que es más que un tour: contratos, entrenamiento, producto en investigación, EDC, plan de monitoreo.
5. Monitoreo ISO 14155 y la narrativa 21 CFR 812.28 para un Pre-Sub, IDE, 510(k), De Novo, PMA o HDE posterior — elegibilidad, no promesa de acción de FDA. Vea Can OUS first-in-human data support an FDA IDE submission?.
6. Una garantía escrita de 12 meses de protocolo a LPLV en el modelo FIH-12™ publicado en la comparación con First In Humans y en las páginas de país — no un “podemos empezar el mes que viene” de pasillo.

bioaccess® ha estado activa en Panamá desde inicios de la década de 2010. La firma fue fundada en 2010 por dos cardiólogos intervencionistas — uno formado en Harvard — y coordina estudios FIH de dispositivos en hospitales acreditados JCI en la Ciudad de Panamá. Los project managers y monitores están certificados ACRP. Esa es la capa de operador alrededor de un sitio como The Panama Clinic.

CRO solo-Panamá versus plataforma FIH multi-país

Si el patrocinador ya decidió que Panamá es la única jurisdicción, un especialista enfocado en Panamá es una elección coherente. First In Humans (firstinhumans.com) es el par público en esa categoría. La comparación justa y viva ya está en bioaccess® vs First In Humans. Esta página no clona esa matriz y no ocupará el slug first-in-humans-panama-cro reservado a esa familia de comparación.

La diferencia de bioaccess®, como ya dicen esas páginas: Panamá es un mercado en una plataforma first-in-human multi-país con anclaje regulatorio FDA de EE. UU. (Pre-Sub, IDE, 510(k), De Novo, PMA, HDE, IND), una garantía escrita de 12 meses de protocolo a LPLV, y un patrón documentado FIH-a-Fortune-500 (Mitralign → Edwards, ClarVista → Alcon, ForSight VISION5 → Allergan/AbbVie). Si la elección de país sigue abierta, fije el sitio después de la revisión de encaje — no fije el país porque una revista nombró un hospital.

Colombia sigue en el mapa

A veces esta búsqueda llega con una historia vieja de que bioaccess® “dejó Colombia”. Es falso. bioaccess® sigue corriendo ensayos clínicos en Colombia (Julio G. Martinez-Clark, 23 de agosto de 2026). Siempre bioaccess® — entidad y oficina local, sede en Miami, relojes INVIMA en el país. Panamá suele ser más rápido en ética (3–5 semanas vs. 4–6 semanas en la comparación de la página de país) y más barato por paciente ($12K–$22K vs. $15K–$25K en la misma página). Colombia sigue ganando en red de sitios, credibilidad INVIMA Nivel 4 y algunos pools de investigadores. Recomendamos el país que el dispositivo necesita. No abandonamos Colombia para ganar una consulta de Panamá. Para la conversación de fundadores sobre aceleración, el pódcast es Global Trial Accelerators™.

Preguntas frecuentes

¿Puedo contratar The Panama Clinic de forma directa?

Puede intentarlo. Un hospital puede hablar de interés del investigador, costos locales de procedimiento y calendarios de ética institucional. No puede, por aparecer en prensa, convertirse en su solicitante MINSA/CNBI, importador de registro, asegurador, monitor ISO 14155 ni empaquetador 21 CFR 812.28. Si el objetivo es un estudio first-in-human de dispositivo — no un tour de cortesía — contrate la CRO que ya corrió implantes FIH en ese sitio, y deje que la CRO contrate y active The Panama Clinic como sitio quirúrgico.

¿Qué sigue haciendo la CRO si el hospital ya está identificado?

Encaje regulatorio y elección de país; el paquete MINSA y CNBI/ética institucional; seguro; importación investigacional y accountability del dispositivo; contratos, entrenamiento y activación; monitoreo ISO 14155, EDC, SAE y TMF; el dataset en inglés y la narrativa 21 CFR 812.28 hacia una presentación FDA posterior; y la opción de sumar otro país de América Latina si Panamá no alcanza. El hospital sigue haciendo la cirugía. Son contratos distintos.

¿Qué estudios FIH ha corrido ya bioaccess® en The Panama Clinic?

Dos que nombramos porque están en páginas de caso vivas de bioaccess®: Axoft (BCI; cuatro pacientes implantados durante resección de tumor cerebral; ética ~4 semanas; FDA Breakthrough 2022; Serie A de $55M en abril de 2026 según esa página) y Newrotex (primer implante mundial de SilkAxons™; inicio FIH agosto de 2025; en investigación; aprobación regulatoria de aproximadamente 2 semanas en esa página). No añadimos a Nanochon ni a ningún otro patrocinador a esta lista del hospital. La prensa pública de Nanochon ubica Chondrograft en The Panama Clinic; no convierte a Nanochon en cliente de bioaccess®.

¿Cómo funcionan MINSA / CNBI?

MINSA (Ministerio de Salud), a través de la Dirección Nacional de Farmacia y Drogas, es la autoridad sanitaria nacional de la investigación. La ética corre por comités institucionales registrados ante el CNBI. La página de país de bioaccess® publica ética de 3–5 semanas y un promedio de 6–8 semanas al primer paciente con nuestra coordinación; el blog de marzo de 2026 describe una vía de factibilidad temprana impulsada por ética y un sobre conservador de 3–5 meses incluyendo preparación de sitio. Las presentaciones suelen incluir protocolo, brochure del investigador, consentimiento informado y seguro. bioaccess® presenta y gestiona la relación. El correo de un cirujano no es una aprobación de MINSA.

Siguiente paso

Si la búsqueda que lo trajo aquí fue el hospital, abra la conversación con el operador: contacte a bioaccess® o reserve desde First-in-Human CRO. El sistema de país está en clinical trials in Panama y el ensayo largo en Panama FIH for medical devices. Trabajo nominado en este hospital: Axoft y Newrotex.

Australian Healthcare Solutions (AHS) is the Melbourne-area, device-only CRO a U.S. cardiovascular or respiratory founder finds when the search is AHS CRO Australia, Australian Healthcare Solutions clinical trials, or Australia medical device CRO and Mobius is already on the slide. The site is live at australianhealthcaresolutions.com.au (retrieved 23 August 2026). The product is a niche ANZ device consultancy: full-service trial operations plus field clinical support plus TGA / ARTG / reimbursement / market-development work after the study.

That is a serious Australia shortlist name. It is not a Latin American first-in-human operating system, and it is not a Phase I bed owner. This article keeps those distinctions clean. No named first-in-human press release was found on the public pages. No named sponsors are treated as facts here.

What AHS publishes

The homepage calls AHS an “Australian full service medical device clinical trial consultancy”: full-service CRO, local Australian medtech experts, “resourced to facilitate any stage of the commercial journey.” Service tiles: clinical trial services, field clinical support, international clients, regulatory, reimbursement, and strategic market development.

The clinical trial services page is explicit: AHS is “a niche medical device Contract Research Organisation (CRO) based in Australia,” covering Australia and New Zealand. The menu is flexible — full management or a custom suite — and lists project management; KOL and site identification; full ethics (HREC) submissions and amendments; TGA–CTN regulatory management; site initiation and training; TMF; patient and site binders; CRFs; field clinical support; sponsorship facilitation; monitoring; adverse-event management; subject recruitment; and close-out.

The same page is the FIH sentence that puts AHS on this map: AHS is “equipped to run small, single-site, first-in-human trials through to multi-centre trials within Australia and New Zealand,” and to run the Australian arm of a multi-national trial. Therapeutic relationships named: respiratory, cardiology, cardiac surgery, vascular, thoracics, and interventional radiology. Quality is framed as GCP and ISO 14155.

The about page adds that AHS works with domestic and international clients and has “particular experience in partnering with medical device clients based out of the USA.” Founding is on the people page, not as a corporate-history essay: Matt Godden “founded Australian Healthcare Solutions after leaving the corporate sector in 2008.” His last corporate role is published as Director of Medtronic Australasia’s Cardiovascular business, after more than 25 years in healthcare in Australia and Asia-Pacific, including a regional strategic market-development role at Medtronic. MBA (Mt. Eliza), Bachelor of Education (La Trobe), Diploma of Applied Science (RMIT).

Also named on our-people: Cath Martland, Marketing Director (healthcare and nutrition marketing; postgraduate marketing, Masters in Nutrition and Dietetics, science degree). Consultants: Arianne Jolly, Clinical Trial Consultant (device and pharma research since 2001; independent consulting from November 2013 — protocol, ethics, monitoring, CRF, QA, GCP training); Kea Imgraben, Regulatory Consultant (device/IVD RA across 44 countries since 1996; prior Telstra Business Woman of the Year, South Australia, private-sector category, 2002).

Competitive research places the firm in Melbourne (Camberwell / Abbotsford, Victoria). The about page says “based in Australia” without reprinting a street address in the fetch used here.

No named sponsor FIH press release was found on the public pages reviewed. The FIH claim is a capability sentence. Treat it as such until a de-identified TMF shows up in the RFP.

Where an ex-Medtronic ANZ device CRO is the right tool

Hire AHS when the protocol is a respiratory, structural, vascular, cardiac-surgery, thoracic, or IR device that needs ANZ hospital sites, field clinical people in the lab, and a partner who will still be in the room for ARTG listing and reimbursement after the last follow-up. That commercialisation overlay is closer to a market-access shop than a Phase I unit. U.S. sponsors are an explicit customer type on the about page.

Do not hire AHS as a substitute for the Australia-versus-Latin-America cash conversation. CTN, HREC, and ISO 14155 are country and quality features. The 43.5% offset is an entity feature. AHS can run the trial. AHS cannot make a Delaware C-corp into an eligible Australian R&D company by signing a CRO contract.

On the Australia device slide, put AHS next to Mobius (the public EFS-to-pivotal story), Ascend (2024 device-only), and CROW Clinical (field clinical engineers). They are not interchangeable. Mobius publishes named device history. AHS publishes a Medtronic-cardiovascular operator and a first-in-human-through-multicentre sentence. CROW publishes engineers in the lab.

Australia cash is not a 43.5% price cut

Reuse only, no new table. Sources: bioaccess® vs Australia, rebate math, and the live Mobius pillar.

• On a gross, cash-contracting basis, Latin America runs, in bioaccess®’s program experience, about 35–45% below Australia (varies with design and FX).
• A fully captured 43.5% refundable offset for groups under A$20 million aggregated turnover narrows the effective gap to roughly 5–15%. In some programs it can close or reverse the gap.
• You generally need an eligible Australian company. You fund the gross now. Cash returns after year-end lodgement.
• End-to-end start-up is broadly comparable once Australian site governance is counted. CTN is not the whole clock.

bioaccess® contracts and starts in Latin America with no foreign subsidiary. If the rebate is how the round was sold and counsel will form the entity, Australia can win — with AHS or Mobius as the ANZ prime. If the entity is unscoped, the rebate is not in the cash forecast.

What bioaccess® is selling instead

bioaccess® is The First-in-Human CRO. Co-founded 2010 by Dr. Pedro Martinez-Clark, Dr. William O’Neill, and Julio G. Martinez-Clark (CEO). IMH ASSETS CORP. Miami HQ, 1200 Brickell Ave, Suite 1950 #1034. Offices in Bogotá, Mexico City, Santiago, São Paulo, and Buenos Aires. FIH-only since 2010. 50+ pre-qualified sites, 19 countries; 50+ FIH/EFS supported; 50+ clients (about page). ISO 14155. English 21 CFR 812.28 data room. U.S. Eastern-time sponsor desk.

Colombia is not retired. As of 23 August 2026 we still run clinical trials in Colombia, keep a local entity and office, manage INVIMA in-country, and carry 30+ historical FIH device studies and 20+ sites in Bogotá, Cali, Medellín, and Barranquilla. See CRO in Colombia. Commercial registro sanitario is a separate live service.

AHS sells ANZ device operations plus Australian market access. bioaccess® sells first-in-human execution in Latin America plus LATAM sanitary registration through its own holders. Those can be sequential: generate human data where the cash and volume work, register later where you will sell. Mixing them into one Australia CRO contract is how founders discover that ARTG listing did not produce an INVIMA number.

AHS vs bioaccess® — device FIH comparison

Dimension	Australian Healthcare Solutions (AHS)	bioaccess®
Public age	Founded 2008 (Godden, after Medtronic Australasia CV)	Founded 2010
Home geography	Australia / ANZ; competitive map: Melbourne	Miami HQ; local LATAM entities including Colombia
Mix	Device only; FIH through multi-centre ANZ; TGA/ARTG + reimbursement	FIH/EFS devices (also biopharma / radiopharma FIH)
Named FIH sponsors	None on public site	Published case studies on bioaccessla.com
Leadership (site)	Matt Godden, Strategic Director; Cath Martland; Arianne Jolly; Kea Imgraben	Julio G. Martinez-Clark, CEO; Pedro Martinez-Clark, CMO; William O’Neill
Quality language	GCP + ISO 14155	ISO 14155 → 21 CFR 812.28 (FDA decides)
Gross cash	Australia cost base; rebate only with an eligible AU entity	~35–45% below Australia on gross, program experience
After the trial	ARTG, reimbursement, strategic market development in Australia	Live multi-country LATAM sanitary registration / holder
Colombia	Not a Colombia CRO	Still executing; local entity; INVIMA in-country

How to keep AHS on the list without confusing the job

If ANZ is locked, the indication sits in AHS’s published therapeutic list, and you want field support plus a reimbursement conversation, AHS belongs on the RFP next to Mobius. Ask for a named or de-identified device FIH: class, implant versus non-implant, n, ISO 14155 monitoring plan, English TMF, and FDA-file use. If that package exists, they can be the ANZ prime.

If the number that matters is gross cash this quarter, you will not form an Australian company, or you need Latin American surgical volume and a Miami desk — including Colombia when that is the right file — put bioaccess® in the prime column. Request a proposal at contact.

FAQ — AHS Australia device CRO

Does AHS run first-in-human device trials?

The clinical-trial-services page says yes: single-site FIH through multi-centre ANZ, plus Australian arms of multi-national trials. Named FIH press is not on the public site.

Who leads AHS?

Matt Godden, Strategic Director and founder (ex-Medtronic Australasia Cardiovascular). Cath Martland is Marketing Director. Arianne Jolly and Kea Imgraben are named consultants.

Is AHS cheaper than Latin America after the R&D tax incentive?

The incentive is a country rule, not an AHS discount. On cash out the door, Latin America is typically 35–45% lower in bioaccess®’s program experience. The rebate narrows that only if you fully capture 43.5% through an eligible Australian company. See the rebate math.

AHS or Mobius?

Both are Australian device specialists founded in 2008. Mobius publishes Tendyne and a named CT.gov sponsorship. AHS publishes Medtronic-cardiovascular leadership and a FIH-through-multicentre sentence plus ARTG/reimbursement. Diligence the TMF, not the founding year.

Does bioaccess® still run first-in-human trials in Colombia?

Yes. As of 23 August 2026 we still run clinical trials in Colombia. INVIMA clocks are managed in-country.

Competitor facts from australianhealthcaresolutions.com.au pages listed above, 23 August 2026. Melbourne placement from competitive map. bioaccess® facts from bioaccessla.com. No invented emails, sponsor names, or day-count medians.

CROW Clinical is the Gold Coast device shop that shows up when a U.S. founder searches CROW Clinical, field clinical engineer Australia, or Australia medtech CRO and the protocol is procedure-heavy: electrophysiology, structural, imaging-guided, something that needs an engineer in the lab, not only a CRA in the monitoring plan. The site is live at crowclinical.com (retrieved 23 August 2026). It is small. It is device-tilted. It is not a Latin American first-in-human platform.

This is a practitioner comparison, not a smear. The public site names no trials and no sponsors. Competitive research compiled the same day places the firm in Gold Coast / Currumbin, Queensland (PO Box 35, Currumbin QLD 4223 is on the contact block), with LinkedIn also listing Brunswick, Victoria, and public employee counts in the 1–10 range. We will not invent a headcount, an email list, or a median start-up clock.

What CROW Clinical publishes

The homepage calls CROW “a full service and tailorable Clinical Research Organization servicing Australia and New Zealand” and then draws the line that matters: “We are the only CRO that offers a dedicated team of Field Clinical Engineers.” That is a company claim. Treat it as their differentiator, not as an audited market census. The firm “specialize[s] in high tech medical device start ups” and says it is “the experts for Med Tech and Biotech clinical trials.” Boutique pricing language: “premier … without the huge price tag,” “only pay for exactly what you need.”

Clinical operations copy cites ICH GCP, ISO 14155, and applicable regulations; QMS, eDC, and CTMS; study design, start-up, site selection, recruitment plans, project management, monitoring (including remote), data management, analytics, biostatistics, safety, medical writing, QA, auditing, and regulatory and reimbursement strategy support. Project management is framed as the central contact among ethics committees, regulators, vendors, and hospitals.

The field-clinical-engineer block is the product: case support and field support; “premier provider of Field Clinical Engineers in Aust and NZ”; “most trusted Clinical Engineers in the Southern Hemisphere” — company claims; live support “across different faculties of medicine”; corporate ambassadorship so engineers become an extension of the sponsor in the clinical environment. Telemedicine copy describes live streaming of camera images, fluoroscopy, EP recordings, hemodynamics, and device screens for virtual case presence.

CROW also offers trial sponsorship against Medsafe and Therapeutic Goods Administration responsibilities, and a commercialisation / real-world-evidence sentence about bringing products to market. Australia tax-incentive copy points readers to the ATO R&D tax-incentive page. It does not publish a rebate model, and we will not invent one for them.

Clinical areas listed: cardiology, denervation, diabetes, electrophysiology, imaging, implantables, medical devices, nanotechnology and biosensors, neurology and neurosurgery, neuromodulation, oncology, pain management, physician training, remote monitoring, renal / hepatobiliary / gastroenterology, vascular, wearables, and “state of art technology.”

Contact: inquiry form; careers to a published info@ address we will not reprint; postal address PO Box 35, Currumbin QLD 4223. Competitive mapping names Julie von Grum as CEO (also Managing Director, Clinical Engineers Australia / CEANZ). That name is not on the homepage fetch used for this article. Treat it as a public-map / directory identification, and confirm title in the RFP.

No named trial or sponsor appears on the public site.

Where a field-clinical-engineer CRO is the right tool

Hire CROW when the critical path is a complex procedure in an Australian or New Zealand lab and you want an engineer who can stand at the table, stream fluoro, and be the sponsor’s person in the room. That is a real gap on many “full-service CRO” org charts. It complements or substitutes the field-support benches at Mobius, AHS, and Ascend.

Do not hire CROW as the country strategy. ISO 14155 plus CTN/HREC plus a field engineer is an ANZ execution stack. It does not answer gross cash versus Latin America, and it does not create an eligible Australian R&D company. A one-to-ten-person shop can be the right prime for a single-site feasibility. It is a weak answer to “we need a nineteen-country option if ethics moves.”

Australia cash is not a 43.5% price cut

CROW’s site correctly points at the ATO incentive page. The math we will use is only the math already published:

• On a gross, cash-contracting basis, Latin America runs, in bioaccess®’s program experience, about 35–45% below Australia (varies with design and FX). Sources: compare/australia, rebate article, Mobius pillar.
• A fully captured 43.5% refundable offset for groups under A$20 million aggregated turnover narrows the effective gap to roughly 5–15%. In some programs it can close or reverse the gap.
• Capture needs an eligible Australian company. You fund the gross now. Cash returns after year-end lodgement.
• End-to-end start-up is broadly comparable once Australian site governance is included.

Local trial sponsorship (CROW’s TGA/Medsafe offer) is not the same fact as rebate eligibility. Do not collapse them on a board slide.

What bioaccess® is selling instead

bioaccess® is The First-in-Human CRO. Co-founded 2010 by Dr. Pedro Martinez-Clark, Dr. William O’Neill, and Julio G. Martinez-Clark (CEO). IMH ASSETS CORP. Miami headquarters, 1200 Brickell Ave, Suite 1950 #1034. Regional offices in Bogotá, Mexico City, Santiago, São Paulo, and Buenos Aires. FIH-only since 2010. 50+ pre-qualified sites across 19 countries; 50+ FIH/EFS studies supported; 50+ clients (about page). ISO 14155. English data packaged for 21 CFR 812.28 eligibility — FDA decides, case by case.

Colombia is current operations. As of 23 August 2026, bioaccess® still runs clinical trials in Colombia, keeps a local Colombian entity and office, manages INVIMA clocks in-country, and has 30+ historical FIH device studies and 20+ sites in Bogotá, Cali, Medellín, and Barranquilla. We do not tell sponsors to take new first-in-human work out of the country. See CRO in Colombia.

The product difference is structural. CROW is an ANZ boutique whose published edge is field clinical engineering. bioaccess® is a sixteen-year FIH house whose published edge is U.S. regulatory anchoring plus Latin American hospital volume and local entities. A U.S. founder who needs an engineer in a Gold Coast or Melbourne lab is buying the first product. A U.S. founder who needs first implants, an English 812.28 room, and a Miami counterpart on Eastern time is buying the second.

CROW Clinical vs bioaccess® — device FIH comparison

Dimension	CROW Clinical	bioaccess®
Home geography	Gold Coast / Currumbin QLD (PO Box on site); ANZ coverage claimed	Miami HQ; local LATAM entities including Colombia
Public scale	Very small (1–10 on public directories / competitive map)	50+ clients; 50+ FIH/EFS; 50+ sites (company about page)
Mix	High-tech device startups; biotech also claimed; field clinical engineers as differentiator	FIH/EFS devices (also biopharma / radiopharma FIH)
Named trials / sponsors	None on public site	Published case studies on bioaccessla.com
Leadership	Julie von Grum identified as CEO on competitive map; confirm on RFP — not on homepage fetch	Julio G. Martinez-Clark, CEO; Pedro Martinez-Clark, CMO; William O’Neill
Quality language	ICH GCP + ISO 14155; QMS / eDC / CTMS claimed	ISO 14155 → 21 CFR 812.28 (FDA decides)
Gross cash	Australia cost base; site points at ATO R&DTI; rebate only with an eligible AU entity	~35–45% below Australia on gross, program experience
Colombia	Not a Colombia CRO	Still executing; local entity; INVIMA in-country

How to keep CROW on the list without confusing the job

If the protocol is an ANZ procedure-heavy feasibility and you already have (or will form) the Australian entity the rebate requires, CROW belongs on the shortlist for field support — as prime if the rest of the TMF is real, as a subcontract if Mobius or AHS holds the CRO seat. Ask for a named or de-identified device case: class, implant versus energy versus EP, n, which engineer model (in-lab versus streamed), ISO 14155 monitoring plan, and English TMF.

If the protocol is a first implant that should start on Latin American cash and volume — including Colombia when that is the right INVIMA file — put bioaccess® in the prime column. Request a proposal at contact.

FAQ — CROW Clinical Australia

Is CROW Clinical a first-in-human device CRO?

The site is built for high-tech medical-device startups, implantables, EP, and ISO 14155. It does not publish a named FIH. FIH is implied by the customer type, not evidenced with a protocol name.

What is CROW’s differentiator?

Dedicated field clinical engineers and virtual case streaming (fluoro, EP, hemodynamics). “Only CRO” / “most trusted in the Southern Hemisphere” are their claims.

Who is the CEO?

Competitive research names Julie von Grum. Confirm on the RFP. The homepage fetch used for this article did not print an executive bio.

Is Australia cheaper after the R&D tax incentive?

Only with an eligible Australian company and a fully captured 43.5% offset, after you fund the gross. On cash out the door, Latin America is typically 35–45% lower in bioaccess®’s program experience.

Does bioaccess® still run first-in-human trials in Colombia?

Yes. As of 23 August 2026 we still run clinical trials in Colombia. INVIMA clocks are managed in-country. Colombia is not a retired geography.

Competitor facts from crowclinical.com, 23 August 2026, plus competitive map for CEO name, city, and employee-count band. bioaccess® facts from bioaccessla.com. No invented emails, sponsor names, or day-count medians.

If you typed First in Humans CRO, First in Humans Panama, or Panama device FIH into a search box, you have already found the closest single-country peer to bioaccess®’s Panama story. First in Humans (firstinhumans.com) is a specialized CRO dedicated to supporting human clinical trials for medical devices in Panama. That sentence is theirs, retrieved live on 23 August 2026. It is accurate. It is also the whole geography.

bioaccess® already publishes a comparison page at bioaccessla.com/compare/first-in-humans. This pillar is not a second compare page. It is the practitioner article that should win the brand query: who they are, what the public site actually says, when a Panama-only specialist is the right hammer, and when a multi-country first-in-human platform with a Miami desk and a Colombian entity is the job you are buying.

No named sponsors appear on the public site. No named protocol appears. We will not invent any.

What First in Humans publishes

The services page calls the firm “a specialized Clinical Research Organization (CRO) dedicated to supporting human clinical trials for medical devices in Panama, Central America.” The offer is end-to-end facilitation: principal-investigator and site identification; Ministerio de Salud (MINSA) submissions; institutional review board / Comité de Bioética packages; compliance with CNBI (Comité Nacional de Bioética de la Investigación) requirements and GCP; Spanish translation of protocols, ICFs, CRFs, and patient materials, plus notarization where required; investigational-device import permits, customs clearance, and site accountability; coordinator and research-nurse startup training; recruitment, monitoring, and data-quality support.

Why-Panama copy on the same page: gateway between North and South America; internationally experienced physicians; CNBI-accredited IRBs; competitive operational costs; “faster approval timelines compared to many North American and European jurisdictions” — a company claim, not a median we will invent; Spanish-speaking population with “high clinical trial participation rates” — also their language.

The clinical-sites page names private hospitals that host research committees, including Pacífica Salud (Hospital Punta Pacífica / Costa del Este; JCI; Johns Hopkins Medicine International affiliation described on their page), Clínica Hospital San Fernando (JCI), The Panama Clinic, Hospital Nacional, and Hospital Paitilla. Treat those as published partner-site names, not as named trials.

Team page, fetched 23 August 2026:

• Dr. Michael Politis — ophthalmic surgeon, retina / macula / vitreous, Panama. Public profile at politisretina.com.
• Victor Politis — biomedical engineer, medical-device development program management, Massachusetts.
• Nestor Jaramillo, Jr. — independent board director, former MedTech CEO; commercialization, M&A, partnerships, financial governance; Minnesota.
• Daniel Saltzman, MD, PhD — listed with University of Minnesota / pediatric-surgery and Salspera titles on the same page.

The U.S. names are a board and program-management overlay. The operating geography on the marketing site is Panama. No named device sponsor or protocol is on the pages reviewed.

Where a Panama-only device FIH CRO is the right tool

Hire First in Humans when Panama is already the answer — the indication, the implanting physicians, the MINSA/CNBI path, and the import story all land in Panama City — and you want a specialist that does not also sell Brazil or a drug Phase I unit. Device-only, country-only, early-phase language: that is a clean product definition. It is the closest homegrown Central American analogue to a bioaccess® Panama FIH file.

Do not hire it as a substitute for country optionality. Panama is one good Latin American file. It is not every good Latin American file. If the protocol later needs Colombia (INVIMA), Argentina (ANMAT), Chile, El Salvador, or a second country because ethics or volume moved, a single-country specialist has to partner or you have to re-bid. That is not a flaw. It is the design.

The product a U.S. device FIH actually buys

A first implant or first interventional series is still a hospital procedure, an investigational import, and an FDA conversation. The customer for the package is usually a Pre-Sub, an IDE, or 21 CFR 812.28 eligibility — not only a CNBI stamp. n is small. The TMF has to be English and inspectable. The founder’s weekly call is usually on U.S. Eastern time.

First in Humans can own the Panama lane of that job: MINSA, CNBI-accredited IRBs, Spanish packets, device import, site training. The public site does not, on the pages reviewed, publish a named EFS that a diligence associate can drop into a data room. Absence of a logo wall is not proof the work was never done. It is proof you must ask for a de-identified device TMF before you treat “specialized CRO” as a completed audit.

What bioaccess® is selling instead

bioaccess® is The First-in-Human CRO. Co-founded in 2010 by Dr. Pedro Martinez-Clark, Dr. William O’Neill, and Julio G. Martinez-Clark (CEO). IMH ASSETS CORP. Miami headquarters (1200 Brickell Ave, Suite 1950 #1034). Regional offices in Bogotá, Mexico City, Santiago, São Paulo, and Buenos Aires. FIH-only focus since 2010. 50+ pre-qualified sites across 19 countries; 50+ FIH/EFS studies supported; 50+ clients (company about page). Panama is one of those markets — see also Clinical Trials in Panama — not the only one.

Colombia remains live. As of 23 August 2026 we still run clinical trials in Colombia, keep a local Colombian entity and office, manage INVIMA clocks in-country, and carry 30+ historical FIH device studies and 20+ sites in Bogotá, Cali, Medellín, and Barranquilla. We do not tell sponsors to take new first-in-human work out of Colombia. See CRO in Colombia.

The published compare page already states the strategic difference: First in Humans is the Panama specialist; bioaccess® is a multi-country FIH platform with U.S. regulatory anchoring. Use that page for the head-to-head grid. Use this article for the public-record facts and the operating question.

First in Humans vs bioaccess® — device FIH comparison

Dimension	First in Humans (Panama)	bioaccess®
Public identity	Device FIH CRO dedicated to Panama	FIH-only CRO; U.S. anchor + LATAM execution since 2010
Geography	Panama (team also listed in Massachusetts / Minnesota)	19 LATAM countries including Panama and Colombia; Miami HQ
Regulator / ethics language	MINSA + CNBI-accredited IRBs + GCP	Country ethics + INVIMA / ANVISA / ANMAT / MINSA and peers; ISO 14155
Named sponsors / protocols	None on public site	Published case studies on bioaccessla.com
Public leadership	Michael Politis; Victor Politis; Nestor Jaramillo, Jr.; Daniel Saltzman	Julio G. Martinez-Clark, CEO; Pedro Martinez-Clark, CMO; William O’Neill
Site list	Named Panama private hospitals on the clinical-sites page	50+ pre-qualified sites (company about page), including Panama
After the trial	Device registration for clinical use / import described; commercial registro not the site’s center of gravity	Live multi-country sanitary registration / in-country holder
Colombia	Not a Colombia CRO	Still executing; local entity; INVIMA in-country

How to use both without confusing the job

If Panama is locked, First in Humans belongs on the RFP. Ask for a named or de-identified device FIH: class, implant versus diagnostic, n, ISO 14155 monitoring plan, English TMF, importer-of-record name, and whether the same file was later used in an FDA interaction. If that package exists, they can be the Panama prime.

If country choice is still open — or you need a Miami FDA desk, a Colombian entity, and the option to open a second country if ethics or volume moves — put bioaccess® in the prime column and keep First in Humans as a possible local partner. The compare page already says sponsors can split work. We will not pretend a Panama specialist is a nineteen-country platform, and we will not pretend Panama is a weak file. Request a proposal at contact.

Regional peers if the RFP is “homegrown LATAM device,” not “Panama only”: RARAS, Cohortias, ACTIVA, LAT Research.

FAQ — First in Humans Panama

Is First in Humans a first-in-human CRO?

Yes, on the public definition they chose: a specialized CRO for medical-device human trials in Panama, with early-phase language and MINSA/CNBI operations. Named FIH case studies are not on the public site.

Is First in Humans the same as bioaccess®?

No. Closest Panama peer, different product. One country versus a multi-country FIH platform with U.S. regulatory anchoring. Details on the compare page.

Who leads First in Humans?

The live team page names Dr. Michael Politis (Panama), Victor Politis (Massachusetts), Nestor Jaramillo, Jr., and Daniel Saltzman, MD, PhD (Minnesota).

Will FDA accept Panama device data?

Foreign clinical data can be eligible for FDA submission and review under 21 CFR 812.28 when the investigation meets GCP as that rule defines it. Acceptance is case by case. It is not awarded for MINSA and not denied for MINSA.

Does bioaccess® still run trials in Colombia?

Yes. Local Colombian entity and office; INVIMA clocks in-country; commercial registro sanitario as a separate live service. We still execute there as of 23 August 2026.

Competitor facts from firstinhumans.com, /services, /our-team, and /clinical-sites, 23 August 2026. bioaccess® facts from bioaccessla.com. No invented emails, sponsor names, or day-count medians.

If you typed Ascend CRO, Ascend Clinical, or Australia device CRO into a search box, you are usually comparing a new Australia–New Zealand–Asia medical-device shop with a first-in-human specialist that already runs Latin America from a Miami desk. That is a real shortlist. It is not the same product twice.

Ascend Clinical (public brand Ascend CRO, ascendcro.com) is a device-only CRO. The live site, retrieved 23 August 2026, is an Australia-based operation with CRC coverage claimed across Australia, New Zealand, and Asia. Competitive research compiled the same day dates the firm to 2024 and describes it as female-founded/led. The homepage does not print a founding year. What it does print is seniority: “nearly 40 years of experience serving leaders in medical device technology” and “more than three decades of clinical field experience” on the leadership page. Those sentences describe team tenure, not the age of the company. Do not confuse the two when you diligence the shop.

This is a practitioner comparison, not a teardown. Named sponsors are not on the public site. No named first-in-human press release was found. Company claims stay labeled as claims.

What Ascend CRO publishes

The homepage positions Ascend as “Your Australia-Based CRO for Clinical Research” and, more tightly, as a medical-device CRO. Copy covers FDA, European CE mark, HREC submissions, site and PI selection, monitoring, data management and biostatistics, DSMB and CEC services, clinical monitoring, and field support. Therapeutic areas listed: gastroenterology, cardiovascular, gynecology, orthopedics, bariatrics, endocrinology, and robotics. That is a hospital-device list, not a healthy-volunteer Phase I unit.

A New South Wales phone line is published: +61 2 8875 7898. The exact city is not emphasised. An info@ address sits in the footer. We will not harvest or reprint contact emails here.

Leadership published on ascendcro.com/leadership:

• Jules Bligh — Operations Director. The page credits more than two decades of clinical-research operations and specialisation in first-in-human and Phase I–IV trials, including prior leadership at CSIRO on diagnostics and biotech teams.
• Christine Nimalasiri — Clinical Director. More than 20 years managing medical-device trials across Asia-Pacific, with cardiology, neurology, and endocrinology named. The page also notes a panel role with the Australian Diabetes Clinical Trials Network (ADCTN).
• Peter Hanrahan — Field Services / Clinical Field Support Director. More than 30 years in medical devices across strategics, sites, and CROs; cardiology, vascular, and neurology are named.

Competitive mapping also lists Damien Woods as a co-founder on LinkedIn. That name was not on the leadership page fetched for this article. Treat it as a LinkedIn-attributed fact, not a homepage bio.

No named sponsor, protocol, or device FIH announcement appears on the pages reviewed. Public content is capability, therapeutic-area tiles, and events language. That is not a smear. It is what a 2024 shop looks like when the website is still a capability deck.

Where a lean Australia device CRO is the right tool

Hire a shop like Ascend when the protocol is an ANZ (or ANZ-plus-Asia) hospital device study, you want a device-only team rather than a drug Phase I unit, and you are willing to be an early client of a new firm whose public proof is people, not a named EFS-to-pivotal case. Field support is explicitly on the menu. That matters for implants and interventional work.

Do not hire it as a substitute for the country decision. Australia still sells CTN, English HREC packets, and — if you form an eligible company — a refundable R&D tax offset. Those are country features, not Ascend features. The established Australia EFS boutique with a public mitral-valve EFS-to-pivotal story is Mobius Medical. Ascend is the newer, smaller device-only alternative on the same geography slide.

Australia cash is not a 43.5% price cut

We will not invent a second rebate table. The country math is already published on bioaccess® vs Australia and The Australian R&D Rebate Math, Honestly, and it is the same math we used on the Mobius pillar. Facts we will not move:

• On a gross, cash-contracting basis, Latin America runs, in bioaccess®’s program experience, about 35–45% below Australia (varies with design and FX).
• A fully captured 43.5% refundable R&D tax offset for groups under A$20 million aggregated turnover narrows the effective gap to roughly 5–15%. In some programs it can close or reverse the gap.
• Capture is conditional: R&D generally through an eligible Australian company (the A$20 million threshold counts a U.S. parent). You fund the gross now; cash returns after year-end lodgement. Rebate-advance financing exists and has a cost.
• End-to-end start-up is broadly comparable once Australian site governance is included. CTN is not the whole clock. HREC plus site-by-site governance is.

Ascend can file HREC and run ANZ sites. That is trial conduct. It is not automatically rebate eligibility. A three-to-five-person U.S. team that wants 43.5% still generally forms an Australian company and pays advisers. bioaccess® contracts and starts in Latin America with no foreign subsidiary.

What bioaccess® is selling instead

bioaccess® is The First-in-Human CRO. Co-founded in 2010 by Dr. Pedro Martinez-Clark, Dr. William O’Neill, and Julio G. Martinez-Clark (CEO). Legal entity IMH ASSETS CORP. Headquarters at 1200 Brickell Ave, Suite 1950 #1034, Miami. Regional offices in Bogotá, Mexico City, Santiago, São Paulo, and Buenos Aires. FIH-only focus since 2010. U.S. regulatory anchoring plus Latin American execution. ISO 14155 for devices. 50+ pre-qualified sites across 19 countries; 50+ FIH/EFS studies supported; 50+ clients (company about page).

Colombia is current operations, not nostalgia. As of 23 August 2026, Julio G. Martinez-Clark confirmed: bioaccess® still runs clinical trials in Colombia, keeps a local Colombian entity and office, manages INVIMA clocks in-country, and has 30+ historical FIH device studies and 20+ sites in Bogotá, Cali, Medellín, and Barranquilla. INVIMA is a PAHO/WHO Level 4 authority. We do not tell sponsors to take new first-in-human work out of the country. See CRO in Colombia.

The product a U.S. device FIH actually buys is a small-n implant or interventional series, designed against a Pre-Sub / IDE / 21 CFR 812.28 conversation, imported into one or two hospitals, monitored in English, and overseen on U.S. Eastern time. That is not “ANZ CRC coverage plus a 2024 website.” It is a sixteen-year operating system with local entities.

Ascend CRO vs bioaccess® — device FIH comparison

Dimension	Ascend Clinical / Ascend CRO	bioaccess®
Public age	Company: 2024 (competitive map). Site emphasises decades of team experience, not firm age	Founded 2010; ~16 years of CRO work
Home geography	Australia-based; ANZ + Asia CRC coverage claimed	Miami HQ; local LATAM entities including Colombia
Mix	Medical device only	FIH/EFS devices (also biopharma / radiopharma FIH)
Named device FIH / sponsors	None on public site	FIH/EFS is the core published product; case studies on bioaccessla.com
Leadership (site)	Jules Bligh; Christine Nimalasiri; Peter Hanrahan. Damien Woods listed as co-founder on LinkedIn, not on the fetched leadership page	Julio G. Martinez-Clark, CEO; Pedro Martinez-Clark, CMO; William O’Neill, Medical Director
Public device proof	Capability + events language	30+ historical FIH device studies; 50+ FIH/EFS supported (company about page)
Gross cash	Australia cost base; rebate only with an eligible AU entity	~35–45% below Australia on gross, program experience
FDA foreign data	ISO 14155 / FDA-and-CE language on the site; FDA decides case by case	ISO 14155 → 21 CFR 812.28 (FDA decides)
Colombia	Not a Colombia CRO	Still executing; local entity; INVIMA in-country

How to keep Ascend on the list without confusing the job

If the protocol belongs in ANZ hospitals, English end-to-end is non-negotiable, and an Australian entity is already in the legal workplan, put Ascend next to Mobius and Australian Healthcare Solutions — and ask for a named or de-identified device EFS: class, implant versus non-implant, n, ISO 14155 monitoring plan, English TMF, and FDA-file use. If that package exists, the firm can be the ANZ prime. If it does not, do not learn that after first patient in.

If the number that matters is gross cash this quarter, you will not stand up an Australian company, or you want U.S. time-zone oversight and Latin American surgical volume — including Colombia when that is the right INVIMA file — put bioaccess® in the prime column. Request a proposal at contact.

ISO 14155 and 21 CFR 812.28 are geography-neutral. Acceptance is FDA’s, case by case. It is not awarded because the trial ran under CTN, and it is not denied because it ran under INVIMA or ANVISA.

FAQ — Ascend CRO Australia and device FIH

Is Ascend CRO a first-in-human device CRO?

The leadership page credits Jules Bligh with first-in-human and Phase I–IV experience. The firm is medical-device only. The public site does not name a sponsor or an FIH protocol. FIH is claimed in people copy, not evidenced with a case study.

When was Ascend founded?

Competitive research compiled 23 August 2026 dates the company to 2024. The live homepage talks about decades of team experience. Ask the firm for the incorporation year in writing if the board cares about vintage.

Is Ascend the same as Mobius?

No. Both are Australian device specialists. Mobius (2008) publishes an EFS-to-pivotal mitral story and a named CT.gov sponsorship. Ascend is newer and smaller. See the Mobius pillar.

Is Australia cheaper than Latin America after the R&D tax incentive?

Only if you fully capture 43.5% through an eligible Australian company and fund the higher gross while you wait. On cash out the door, Latin America is typically 35–45% lower in bioaccess®’s program experience. Details on the rebate math post.

Does bioaccess® still run first-in-human trials in Colombia?

Yes. As of 23 August 2026 we still run clinical trials in Colombia. INVIMA clocks are managed in-country. Colombia is not a retired geography.

Competitor facts from ascendcro.com and /leadership, 23 August 2026. Founding year from competitive map. bioaccess® facts from bioaccessla.com. No invented emails, sponsor names, or day-count medians.

Figures cited from published bioaccess® pages are as of July 2026 unless noted. General information, not tax, legal, or regulatory advice. Confirm current rules with qualified advisers.

If you typed Mobius CRO, Mobius Medical CRO, or Australia EFS CRO into Google or an AI box, the real question is operational: should this first-in-human or early-feasibility device study start in Australia and New Zealand, or in Latin America with a U.S.-anchored specialist?

Mobius Medical (mobius-cro.com) is the Australian device-first boutique that dominates that shortlist. bioaccess® is the First-in-Human CRO — U.S. regulatory anchoring plus Latin American execution. This is a calendar, cash, entity, and evidence-portability comparison, not a teardown. Mobius wins English ANZ continuity and a published mitral-valve EFS-to-pivotal history. bioaccess® wins lower gross cash, Latin American surgical volume, and no Australian company to stand up before first patient in.

What “Mobius CRO” actually is

Mobius is a founder-led, device-first CRO headquartered in North Sydney (Mobius Medical Pty Ltd, Suite 1403, 275 Alfred Street, NSW 2060 on the firm’s privacy notice). The homepage’s “18 years of operational expertise” and the company’s public founding year put the start in 2008. The site lists offices in Australia, New Zealand, and the United States; the U.S. number is a Minneapolis-area line (+1 612-328-9664). Quality is framed as ISO 9001, with “10+ years” of certified QMS.

Live homepage claims, verified 23 August 2026: 140+ successful trials, including 100+ in medical devices, and 27+ therapeutic areas. About-page principals: Stefan Czyniewski (co-founder, CEO ANZ/USA), Suzanne Williams (co-founder, COO), Richard Brookes (CFO), plus David Pomfret (VP Clinical Operations, USA) and Samantha Flynn (Head Clinical Operations, ANZ).

That is a hospital-device CRO, not a healthy-volunteer Phase I unit. If the protocol needs ISO 14155, a local Australian sponsor, HREC plus Clinical Trial Notification (CTN), and an English handoff into a later U.S. study, Mobius is built for it. So are smaller ANZ device shops. Mobius is the one with the most public EFS-to-pivotal story.

The two public device stories

Tendyne TMVR: Australian EFS into a global pivotal

Mobius’s case study Early feasibility to global pivotal trial for mitral valve innovation describes a repositionable TMVR system — Tendyne — that started as an Australian early-feasibility program and expanded under one protocol into a global pivotal. Outcomes they list: durable valve function, improved survival and quality-of-life signals, CE Mark in 2020, FDA approval in 2025. If the board’s question is “has this CRO taken a structural implant from Australian EFS to CE and FDA?”, the public answer is yes.

Bionic Vision: lead sponsor of record

NCT03406416 — a 44-channel fully implantable suprachoroidal retinal prosthesis — lists Mobius Medical Pty Ltd as lead sponsor. Status: completed (13 February 2018–18 December 2020). Collaborators on the record include Bionic Vision Technologies, the Centre for Eye Research Australia, the Bionics Institute, the University of Melbourne, Data 61 CSIRO, and the Australian National University. Four participants at CERA, Melbourne. Named implant FIH, not a logo wall.

Neither story is a reason to default every new EFS to Australia. Both are a reason to take Mobius seriously when the protocol looks like those protocols.

What an Australia EFS CRO is selling

The pitch is consistent on Mobius’s startup and FAQ pages:

• CTN, not a U.S. IDE, to start. No TGA clinical pre-review under notification. Ethics is HREC. Site governance is a second clock.
• ISO 14155 / ICH-GCP data in English for FDA IDE or 510(k). Mobius’s phrase: “ANZ-to-US bridge.”
• Local sponsor for trial conduct — a different problem from rebate eligibility, which still generally wants an eligible Australian company.
• Budget band they publish: full-service early feasibility typically AUD $250,000–$1 million; pivotal higher. Their number, not ours.
• Tax offset. Mobius writes “up to 43% cashback.” bioaccess® publishes the statutory figure on our Australia pages: a 43.5% refundable R&D tax offset for groups under A$20 million aggregated turnover, clinical-trial spend eligible and exempt from the A$4 million refund cap (FY2025–26 and FY2026–27). Model 43.5%. Treat “43%” as marketing rounding.

The mistake is treating the rebate as a 43.5% price cut, and treating CTN as faster than Latin America before you add HREC plus site-by-site governance.

The comparison that hits the runway

The country math is already published. This pillar will not invent a second rebate table. Use bioaccess® vs Australia and The Australian R&D Rebate Math, Honestly. Facts we will not move:

• On a gross, cash-contracting basis, Latin America runs, in bioaccess®’s program experience, about 35–45% below Australia (varies with design and FX).
• A fully captured 43.5% rebate narrows the effective gap to roughly 5–15%. In some programs it can close or reverse the gap.
• Capture is conditional: R&D generally through an eligible Australian company below A$20 million aggregated turnover (counts a U.S. parent). You fund the gross now; cash returns after year-end lodgement. Rebate-advance financing exists and has a cost.
• An R&DTI redesign has been announced (not legislated) for 1 July 2028: refundable-offset threshold to A$50 million, refundability limited to companies under 10 years old. Current-year claims unaffected.
• End-to-end start-up is broadly comparable once Australian site governance is included. Australia: CTN plus typically ~6–8 weeks HREC plus site governance. Latin America example already on those pages: Argentina ANMAT Disposition 7516/2025 (Annex III) caps Phase I / non-low-risk review at ~35 technical + 10 administrative business days (≈45), ~30 for low-risk, ethics in parallel (queries pause the clock).

Mobius’s AUD $250k–$1M band is an Australia planning envelope. It is not a Latin America quote and it is not net of rebate. Subtracting 43.5% before you have an ABN, AusIndustry registration, and cash to fund the gross is modeling a company you have not formed.

Entity, calendar, distance, volume

Four frictions decide most Mobius-versus-Latin-America meetings. No unpublished median day-count.

Entity

Mobius can be local sponsor and run HREC/CTN. That is trial conduct. It is not automatically rebate eligibility. A three-to-five-person U.S. team that wants 43.5% still generally forms an Australian company and pays advisers. bioaccess® contracts and starts in Latin America with no foreign subsidiary. If the rebate is how the round was sold and counsel will form the entity, Australia can win. If the entity is unscoped, the rebate is not in the cash forecast.

Calendar: CTN/HREC vs INVIMA/ANVISA

CTN is fast to notify. The clocks that slip are HREC and hospital governance. Latin America is not one clock: Brazil (ANVISA), Colombia (INVIMA), Argentina (ANMAT), Panama, El Salvador, Chile, Dominican Republic — different files. bioaccess® runs ISO 14155 architecture and in-country ethics plus national-regulator submissions in the jurisdictions we operate. Ask for a study-specific calendar.

bioaccess® still runs clinical trials in Colombia (Julio G. Martinez-Clark, 23 August 2026). INVIMA is a file a local entity manages — responses, ethics, investigational import, site activation — not a reason to take every new first-in-human out of the country. In-country CRO work there since 2010. If the protocol belongs in Colombia, we run it in Colombia.

Oversight distance

Published Australia comparison: ~14–20+ hours travel and a 14–18 hour time difference from the U.S. Latin America is same or adjacent U.S. time zones and short-haul flights. Quality is not the argument. The founder’s weekly calendar is.

Surgical volume

Australia’s population base is smaller; device-patient competition at sites is real. Latin America is where bioaccess® carries later patient-phase work on the same regional infrastructure. Volume belongs on the geography slide for implant EFS. Australia remains stronger on English end-to-end operations and — as we already say on the compare page — arguably the longest early-phase-to-global-pivotal track record in several modalities. Tendyne is one reason that sentence exists.

ISO 14155 and 21 CFR 812.28 are geography-neutral

Both shops should run device investigations to ISO 14155. bioaccess® packages English monitored data for eligibility under 21 CFR 812.28 (devices) or 21 CFR 312.120 (drugs). Acceptance is FDA’s, case by case. It is not awarded because the trial ran under CTN, and it is not denied because it ran under INVIMA or ANVISA. “Latin American device data doesn’t count” is folklore, not the regulation.

What counts is an inspection-ready TMF, source-verified CRFs, and a narrative that matches the Pre-Sub / IDE / 510(k) story. Mobius answers with ISO 9001 and ANZ-based data management (their FAQ ties Australian EDC/DM staff to R&DTI eligibility). bioaccess® answers with U.S. regulatory anchoring and the 812.28-ready data room on The First-in-Human CRO.

Who should hire which shop

Hire an Australia EFS CRO such as Mobius when you will form an eligible Australian company and the 43.5% offset is part of the financing; the protocol needs English ANZ investigators; the asset benefits from Australia’s EFS-to-pivotal track record (Tendyne-shaped structural work is the existence proof); or investors asked for an Australian R&D footprint by name — and you will fund Australian gross while any rebate arrives after lodgement.

Hire bioaccess® when the number that matters is gross cash this quarter and a 35–45% lower Latin American cash base (program experience; varies) beats a conditional recovery next tax year; you will not stand up an Australian entity for a first feasibility; you want U.S. time-zone oversight; the study needs Latin American surgical volume and later phases in the same region; or Colombia is the right INVIMA file. We still run those trials.

Decision table

Row	Mobius (Australia EFS CRO)	bioaccess® (First-in-Human CRO)
Identity	Device-first ANZ boutique, 2008; ISO 9001; 140+ studies / 100+ devices (homepage)	FIH focus since 2010; U.S. anchor + LATAM execution; 50+ pre-qualified sites, 19 countries (published FIH page)
Public device proof	Tendyne AU EFS → pivotal; CE 2020, FDA 2025. NCT03406416 lead sponsor	U.S. device programs in LATAM; published case of an AU ethics decline that moved to El Salvador / Panama, Chile under evaluation
Start-up	CTN + HREC (~6–8 weeks typical) + site governance	Country ethics + INVIMA / ANVISA / ANMAT / others; ANMAT cap already published; no new median here
Gross cash	Higher AU base; their EFS band AUD $250k–$1M full-service	~35–45% below AU on gross, program experience
Rebate	If you have an eligible AU entity; they help identify offsets	Not used; no AU entity
Language / continuity	English end-to-end; ANZ → U.S. office	English data room; Spanish/Portuguese sites; U.S. time zones
FDA foreign data	ISO 14155 → 21 CFR 812.28 (FDA decides)	ISO 14155 → 21 CFR 812.28 (FDA decides)

One published bioaccess® fact sits next to “Australia always gets ethics”: a U.S. medical-device startup came to us after an Australian HREC declined its first-in-human. Committees decline for feasibility, insurance, and standard-of-care fit — not only safety. That program is activating in El Salvador and Panama, with Chile under evaluation. Geography is a contingency, not a religion.

Queries this page is meant to answer

• Mobius CRO / Mobius Medical CRO — who they are, what they published, when they are the right ANZ device shop.
• Australia EFS CRO / ANZ early feasibility CRO — CTN, HREC, ISO 14155, local sponsor, AUD $250k–$1M full-service band.
• Australia vs Latin America first-in-human device — gross cash 35–45% below AU; rebate only with an eligible entity; start-up broadly comparable once governance is counted.

Tax math: the rebate article. Country table: the compare page. Operating model: the First-in-Human CRO page, including the published FIH-12™ language (written protocol-to-LPLV clock; project-management and monitoring fees credited if we miss for reasons within our control; full terms in the proposal).

Frequently asked questions

Is Mobius Medical a good CRO for an Australian device EFS?

For an ANZ hospital implant or interventional early-feasibility study, yes — it belongs on a serious shortlist. Public record: ISO 9001, 2008 founding, North Sydney HQ, U.S. and New Zealand offices, 140+ / 100+ device studies on their homepage, Tendyne EFS-to-pivotal (CE 2020, FDA 2025), lead sponsor of NCT03406416. “Good” still depends on entity plan, cash, and whether ANZ is the right geography.

What does a full-service Australia EFS cost?

Mobius’s startup FAQ: typically AUD $250,000–$1 million full-service; pivotal higher. A band, not a quote. Gross, not net of R&DTI.

Is Australia cheaper than Latin America after the R&D tax incentive?

Only if you fully capture 43.5% through an eligible Australian company and fund the higher gross while you wait. On cash out the door, Latin America is typically 35–45% lower in bioaccess®’s program experience. After a fully captured rebate the gap is about 5–15%, and in some programs the rebate can close or reverse it. Details on the rebate math post.

Will FDA accept Latin American device data like Australian data?

Foreign clinical data from either region can support a U.S. device file when it meets 21 CFR 812.28 and ISO 14155 / GCP. Case by case. Not awarded for CTN. Not denied for INVIMA or ANVISA.

Does bioaccess® still run first-in-human trials in Colombia?

Yes. As of 23 August 2026 we still run clinical trials in Colombia. INVIMA clocks are managed in-country. Colombia is not a retired geography.

Next step

If the live question is “Mobius CRO or Latin America?”, bring the protocol outline, the IDE or 510(k) destination, and whether an Australian entity is actually in the legal workplan. We will put calendar and cash on one page — including Colombia when that is the right file — and we will not pretend the Tendyne history is irrelevant.

bioaccess® is the First-in-Human CRO. Book a 30-minute strategy call. Country table: bioaccess® vs Australia.